RYTM (Rhythm Pharmaceuticals, Inc. Common Stock) Stock Analysis - Financials

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a publicly traded Healthcare sector company. As of May 21, 2026, RYTM trades at $90.54 with a market cap of $5.95B and a P/E ratio of -28.53. RYTM moved +3.78% today. Year to date, RYTM is -11.02%; over the trailing twelve months it is +41.91%. Its 52-week range spans $45.91 to $122.20. Analyst consensus is strong buy with an average price target of $137.64. Rallies surfaces RYTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are RYTM's key financials?

RYTM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RYTM recently traded at $90.54. Market cap is $5.95B. P/E ratio is -28.53. Revenue is $217.16M.

RYTM Key Metrics

Key financial metrics for RYTM
MetricValue
Price$90.54
Market Cap$5.95B
P/E Ratio-28.53
EPS$-3.13
Dividend Yield0.00%
52-Week High$122.20
52-Week Low$45.91
Volume601
Avg Volume0
Revenue (TTM)$217.16M
Net Income$-202.68M
Gross Margin89.41%

RYTM Annual Financials

YearRevenueNet IncomeEPS
2025$189.76M$-196.54M$-3.11
2024$130.13M$-260.60M$-4.34
2023$77.43M$-184.68M$-3.20
2022$23.64M$-181.12M$-3.47

Latest RYTM News

Recent RYTM Insider Trades

  • German Christopher Paul sold 5.61K (~$502.79K) on Mar 4, 2026.
  • Smith Hunter C sold 1.31K (~$131.15K) on Feb 19, 2026.
  • Smith Hunter C sold 1.69K (~$170.75K) on Feb 19, 2026.

RYTM Analyst Consensus

14 analysts cover RYTM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.64.

Common questions about RYTM

What are RYTM's key financials?
RYTM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RYTM recently traded at $90.54. Market cap is $5.95B. P/E ratio is -28.53. Revenue is $217.16M.
Is RYTM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RYTM. It does not provide personalized investment advice.
RYTM

RYTM